Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Neoadjuvant Durvalumab Plus Chemo Boosts pCR Vs Chemo Alone in Gastric/GEJ Cancers Regardless of Region

January 19th 2024

Durvalumab plus neoadjuvant FLOT improved pCR vs chemotherapy alone in patients with resectable gastric and GEJ cancers, irrespective of region.

Tiragolumab Plus Atezolizumab and Chemotherapy Offers Survival Benefit Over Chemotherapy Alone in ESCC

January 19th 2024

Tiragolumab plus atezolizumab and chemotherapy produced superior survival benefit vs chemotherapy for patients with esophageal squamous cell carcinoma.

Dr Shah on the 5-Year Survival Outcomes From the KEYNOTE-590 Study in Esophageal Cancer

January 19th 2024

Manish A. Shah, MD, discusses 5-year outcomes from KEYNOTE-590 of first-line pembrolizumab plus chemotherapy in patients with advanced esophageal cancer.

ASKB589 Plus CAPOX and Sintilimab Demonstrates Early Efficacy in Gastric/GEJ Cancers

January 18th 2024

ASKB589 demonstrated anti-tumor activity in combination with capecitabine and oxaliplatin plus sintilimab in gastric or gastroesophageal junction cancers.

Nivolumab/Chemo Combination Sustains Survival Improvement in Gastric/GEJ Cancers

January 18th 2024

Nivolumab plus chemotherapy improved PFS and OS vs chemotherapy alone in patients with advanced gastric, gastroesophageal junction, and esophageal cancers, according to 4-year data from the phase 3 CheckMate 649 study.

First-Line Nivolumab Plus Chemotherapy Shows Real-World Efficacy in Gastric/GEJ/Esophageal Cancers

January 18th 2024

Real-world findings demonstrated a favorable survival benefit with nivolumab plus chemotherapy in advanced gastroesophageal adenocarcinoma.

Dr. Van Cutsem on Primary Findings from the SPOTLIGHT and GLOW Trials in Metastatic Gastric Cancer

February 27th 2023

Eric Van Cutsem, MD, PhD, discusses primary efficacy and safety findings from the phase 3 SPOTLIGHT and GLOW trials investigating the monoclonal antibody zolbetuximab in metastatic gastric cancer.

TTFields With Chemotherapy Under Investigation in Locally Advanced Pancreatic Cancer

February 23rd 2023

Tumor treating fields concomitant with gemcitabine and nab-paclitaxel is being compared with chemotherapy alone in the frontline treatment of patients with aggressive, locally advanced pancreatic cancer as part of the phase 3 PANOVA-3 trial.

Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing

January 23rd 2023

The high concordance rate between gastric and breast cancer HER2 scoring algorithms suggest that either may be used in the metastatic colorectal cancer setting.

Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC

January 22nd 2023

The addition of mFOLFOX6 or FOLFIRI to the combination of encorafenib and cetuximab elicited encouraging antitumor activity and safety in patients with BRAF V600E-mutant metastatic colorectal cancer.

Patient-specific Marker Tracking Approach May Better Detect MRD in CRC

January 22nd 2023

A novel Burning Rock patient-specific prognostic and potential therapeutic marker tracking approach demonstrated improved sensitivity in detecting circulating tumor DNA and identifying molecular residual disease compared with other approaches in patients with colorectal cancer following surgery.

ctDNA Could Assist in Early Response Assessment in Advanced CRC

January 22nd 2023

Circulating tumor DNA could serve as an ideal biomarker to assess early response in patients with advanced colorectal cancer due to its short half-life compared with other tumor biomarkers, and it could enable the use of adaptive clinical study designs in the future.

Dr. Kopetz on Safety Lead-in Data from the BREAKWATER Trial in BRAF V600E–Mutant mCRC

January 22nd 2023

Scott Kopetz, MD, PhD, FACP, discusses the safety lead-in data from the phase 3 BREAKWATER trial in patients with BRBRAF V600E–mutant metastatic colorectal cancer.

Dr. Wainberg on Liposomal Irinotecan/NALIRIFOX vs Nab-paclitaxel/Gemcitabine in PDAC

January 22nd 2023

Zev A. Wainberg, MD, discusses the evaluation of liposomal irinotecan plus 5-fluorouracil leucovorin, and oxaliplatin vs nab-paclitaxel plus gemcitabine in the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Neoadjuvant Chemoradiation Plus Veliparib or Pembrolizumab Fails to Improve NAR Score in Locally Advanced Rectal Cancer

January 21st 2023

Both veliparib plus total neoadjuvant therapy and pembrolizumab plus total neoadjuvant therapy failed to improve short-term outcomes in unselected patients with locally advanced rectal cancer.

Bevacizumab Plus TAS-102 Increases Survival and DCR in mCRC

January 21st 2023

Third-line bevacizumab plus trifluridine/tipiracil demonstrated a survival and disease control benefit vs trifluridine/tipiracil alone in patients with refractory metastatic colorectal cancer and all clinically relevant subgroups.

Newer Therapies Demonstrate Real-world Benefit Vs Sorafenib in First-line HCC

January 21st 2023

Newer frontline therapies demonstrated a real-world improvement in survival and responses compared with sorafenib in patients with hepatocellular carcinoma.

Dr. Tabernero on the Efficacy of Bevacizumab Plus TAS-102 in Refractory mCRC

January 21st 2023

Josep Tabernero, MD, PhD, discusses findings from the phase 3 SUNLIGHT trial investigating the combination of bevacizumab plus trifluridine/tipiracil vs TAS-102 alone in patients with refractory metastatic colorectal cancer.

Dr. Dawson on the Addition of SBRT to Sorafenib in Locally Advanced HCC

January 21st 2023

Laura Dawson, MD, FRCPC, discusses results from the phase 3 NRG/RTOG 1112 trial of stereotactic body radiation therapy plus sorafenib compared with sorafenib alone in patients with locally advanced hepatocellular carcinoma.

CD40-Directed SEA-CD40 Combo Denotes Antitumor Activity in Pancreatic Ductal Adenocarcinoma

January 21st 2023

The combination of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab demonstrated early evidence of efficacy in patients with metastatic pancreatic ductal adenocarcinoma, according to updated results from the phase 1 SGNS40-001 study.